Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$258K Sell
2,005
-1,280
-39% -$150K 0.07% 144
2026
Q1
$395K Buy
3,285
+42
+1% +$4.85K 0.09% 135
2025
Q4
$366K Sell
3,243
-418
-11% -$39.2K 0.07% 151
2025
Q3
$315K Buy
+3,661
New +$302K 0.07% 164
2025
Q2
Sell
-2,836
Closed -$255K 211
2025
Q1
$255K Sell
2,836
-287
-9% -$26.8K 0.08% 172
2024
Q4
$311K Buy
3,123
+782
+33% +$80.6K 0.09% 161
2024
Q3
$266K Sell
2,341
-30
-1% -$3.56K 0.08% 172
2024
Q2
$294K Sell
2,371
-31
-1% -$3.99K 0.09% 164
2024
Q1
$317K Buy
2,402
+113
+5% +$13.9K 0.09% 162
2023
Q4
$250K Buy
+2,289
New +$238K 0.08% 176
2022
Q3
Sell
-238
Closed -$217 197
2022
Q2
$217 Buy
+238
New +$21.1K 0.06% 112

Other funds holding MRK

Apeiron RIA's MRK Position: Q2 2026 in Review

Apeiron RIA reduced its Merck (MRK) stake by 39% in Q2 2026, selling an estimated $150K and leaving 2,005 shares worth $258K. The position accounts for 0.07% of the portfolio, ranked #144.

Apeiron RIA first reported a position in MRK in Q2 2022 and has held it in 11 quarters since. The position peaked at $395K in Q1 2026. 1,769 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Apeiron RIA held 2,005 shares of Merck worth $258K as of Q2 2026.
  • Apeiron RIA sold 1,280 Merck shares in Q2 2026, an estimated $150K.
  • Merck made up 0.07% of Apeiron RIA's portfolio in Q2 2026, its #144 holding.
  • Apeiron RIA first reported a position in Merck in Q2 2022 and has held it in 11 quarters since.
  • Apeiron RIA's Merck position peaked at $395K in Q1 2026.
  • 1,769 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Apeiron RIA's 13F filing for Q2 2026, filed 16 Jul 2026.